Cochrane · systematic review · CD013109
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
Hasegawa, T, Nishiwaki, H, Ota, E, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 4 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aldosterone antagonists (spironolactone or eplerenone) versus control (placebo or standard care) for people with chronic kidney disease requiring dialysis
Population: people with chronic kidney disease requiring dialysis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause) Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) | RR 0.45 [0.3, 0.67] | 9 studies · 1119 participants | Moderate Downgraded: imprecision |
Death (cardiovascular) Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) | RR 0.37 [0.22, 0.64] | 6 studies · 908 participants | Moderate Downgraded: imprecision |
Cardiovascular and cerebrovascular morbidity Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) | RR 0.38 [0.18, 0.76] | 3 studies · 328 participants | Moderate Downgraded: imprecision |
Hyperkalaemia Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) | RR 1.41 [0.72, 2.78] | 9 studies · 981 participants | Low Downgraded: imprecision |
Gynaecomastia Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) | RR 5.95 [1.93, 18.28] | 4 studies · 768 participants | Moderate Downgraded: imprecision |
Left ventricular mass Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) | no estimate extracted | 7 studies · 562 participants | Low Downgraded: imprecision |